Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,472
datasets available to search
ShareScore release 0.9.0
Dataset results
1,472 results for “EGFR”
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
ClinicalTrials.gov study NCT07100080. IPD Sharing: YES. Countries: 25. Publications: 0.
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
ClinicalTrials.gov study NCT05079022. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
ClinicalTrials.gov study NCT07063329. IPD Sharing: NO. Countries: 1. Publications: 0.
Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
ClinicalTrials.gov study NCT03461185. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
ClinicalTrials.gov study NCT06752408. IPD Sharing: NO. Countries: 1. Publications: 0.
S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
ClinicalTrials.gov study NCT02631460. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
ClinicalTrials.gov study NCT07183189. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
ClinicalTrials.gov study NCT04862780. IPD Sharing: NO. Countries: 10. Publications: 0.
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resectio
ClinicalTrials.gov study NCT07128199. IPD Sharing: NO. Countries: 24. Publications: 0.
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
ClinicalTrials.gov study NCT07327411. IPD Sharing: NO. Countries: 1. Publications: 0.
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB
ClinicalTrials.gov study NCT02326285. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
ClinicalTrials.gov study NCT06015568. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
ClinicalTrials.gov study NCT05256290. IPD Sharing: NO. Countries: 1. Publications: 0.
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
ClinicalTrials.gov study NCT07089641. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
ClinicalTrials.gov study NCT01053936. IPD Sharing: YES. Countries: 1. Publications: 0.
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
ClinicalTrials.gov study NCT06355609. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
ClinicalTrials.gov study NCT07338396. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT05442060. IPD Sharing: NO. Countries: 1. Publications: 0.
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
ClinicalTrials.gov study NCT03784599. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C
ClinicalTrials.gov study NCT03623750. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.